Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22589690 | 1.00 | SLC5A2 (0.72) | SLC5A2SLC5A1 | |
| SCHEMBL25343707 | 1.00 | SLC5A2 (0.72) | SLC5A2SLC5A1 | |
| SCHEMBL20404252 | 1.00 | SLC5A2 (0.72) | SLC5A2SLC5A1 | |
| SCHEMBL26892208 | 1.00 | SLC5A2 (0.72) | SLC5A2SLC5A1 | |
| SCHEMBL1146844 | 1.00 | SLC5A2 (0.72) | SLC5A2SLC5A1 | |
| SCHEMBL2861049 | 0.97 | SLC5A2 (0.67) | SLC5A2SLC5A1 | |
| SCHEMBL13153692 | 0.96 | SLC5A2 (0.66) | SLC5A2SLC5A1 | |
| SCHEMBL13153693 | 0.95 | SLC5A2 (0.65) | SLC5A2SLC5A1 | |
| SCHEMBL13153658 | 0.90 | SLC5A2 (0.67) | SLC5A2SLC5A1 | |
| SCHEMBL2868243 | 0.89 | SLC5A2 (0.78) | SLC5A2SLC5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10220017-B2 | Liquid pharmaceutical compositions comprising SGLT-2 inhibitors | BOEHRINGER INGELHEIM VETMEDICA GMBH | 2019-03-05 | — | — | US | claimed |
| EP-3197429-B1 | COMBINATION TREATMENT OF SGLT2 INHIBITORS AND DOPAMINE AGONISTS FOR PREVENTING METABOLIC DISORDERS IN EQUINE ANIMALS | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2024-05-22 | — | — | EP | disclosed |
| WO-2023227492-A1 | AQUEOUS PHARMACEUTICAL COMPOSITIONS COMPRISING SGLT-2 INHIBITORS | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2023-11-30 | — | — | WO | disclosed |
| EP-3865120-A1 | PRESERVED ETHERIFIED CYCLODEXTRIN DERIVATIVES CONTAINING LIQUID AQUEOUS PHARMACEUTICAL COMPOSITION | Boehringer Ingelheim Vetmedica GmbH (DE) | 2021-08-18 | — | — | EP | disclosed |
| CN-104470908-A | Crystalline complex of 1-cyano-2- (4-cyclopropyl-benzyl) -4- (beta-D-glucopyranos-1-yl) -benzene, method for preparing same and use thereof for preparing a medicament | BOEHRINGER INGELHEIM VETMED | 2015-03-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10220017-B2 | Liquid pharmaceutical compositions comprising SGLT-2 inhibitors | SLC5A2, SLC5A1, SLC2A2 | SLC5A2 1/4885SLC5A1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.